From the Research
There is no recommended dosage of ivermectin for pancreatic cancer in humans because ivermectin is not approved or proven effective for treating pancreatic cancer. Ivermectin is an antiparasitic medication primarily used to treat infections caused by certain parasites, not cancer. While some laboratory studies have explored ivermectin's potential effects on cancer cells, these findings have not translated to proven clinical benefits in human cancer patients 1. Currently, standard treatments for pancreatic cancer include surgery, chemotherapy, radiation therapy, and targeted therapies based on the cancer stage and patient factors.
Some studies have investigated the potential anticancer effects of ivermectin, including its ability to inhibit the proliferation of pancreatic cancer cells in vitro 2, 1. However, these findings are based on laboratory experiments and have not been confirmed in human clinical trials. The most recent study on this topic, published in 2025, found that ivermectin combined with recombinant methioninase (rMETase) synergistically eradicated MiaPaCa-2 pancreatic cancer cells in vitro 1. However, this study was conducted in a laboratory setting and does not provide evidence for the safe and effective use of ivermectin in human cancer patients.
Anyone diagnosed with pancreatic cancer should follow treatment plans prescribed by oncologists and other healthcare providers specializing in cancer care. Self-medicating with ivermectin for cancer treatment could delay appropriate medical care and potentially cause harm through side effects or drug interactions. The current standard of care for pancreatic cancer is based on a multidisciplinary approach, including surgery, chemotherapy, radiation therapy, and targeted therapies, as outlined in recent reviews of pancreatic cancer treatment 3.
In summary, while some laboratory studies suggest that ivermectin may have potential anticancer effects, there is currently no recommended dosage of ivermectin for pancreatic cancer in humans, and patients should follow established treatment plans under the guidance of qualified healthcare providers.